NASDAQ:IRMDIradimed Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Iradimed Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.93 -0.27 (-1.12 %) (As of 07/7/2020 04:00 PM ET) Add Compare Share Today's Range$23.76Now: $23.93▼$24.3250-Day Range$20.55MA: $22.98▼$24.3552-Week Range$14.41Now: $23.93▼$28.43Volume37,500 shsAverage Volume51,890 shsMarket Capitalization$288.36 millionP/E Ratio31.08Dividend YieldN/ABeta1.37 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.Read More Beat the Market (BTM) Rank™ 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, Iradimed has a potential upside of 25.4% from its current price of $23.93.Amount of Analyst CoverageIradimed has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesIradimed has received 226 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIradimed has received 242 “underperform” votes. (Add your “underperform” vote.)Community SentimentIradimed has received 51.71% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote “Outperform” if you believe IRMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIradimed does not currently pay a dividend.Dividend GrowthIradimed does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iradimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $80,040.00 in company stock.Percentage Held by Insiders50.90% of the stock of Iradimed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.91% of the stock of Iradimed is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Iradimed are expected to grow by 189.19% in the coming year, from $0.37 to $1.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iradimed is 31.08, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.73.Price to Earnings Ratio vs. SectorThe P/E ratio of Iradimed is 31.08, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.43.Price to Book Value per Share RatioIradimed has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IRMD Previous Symbol CUSIPN/A CIK1325618 Webwww.iradimed.com Phone407-677-8022Debt Debt-to-Equity Ratio0.05 Current Ratio12.40 Quick Ratio11.54Price-To-Earnings Trailing P/E Ratio31.08 Forward P/E Ratio64.68 P/E GrowthN/A Sales & Book Value Annual Sales$38.52 million Price / Sales7.49 Cash Flow$0.95 per share Price / Cash Flow25.31 Book Value$4.83 per share Price / Book4.95Profitability EPS (Most Recent Fiscal Year)$0.78 Net Income$9.63 million Net Margins24.65% Return on Equity17.99% Return on Assets15.02%Miscellaneous Employees95 Outstanding Shares12,050,000Market Cap$288.36 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable NASDAQ:IRMD Rates by TradingView Receive IRMD News and Ratings via Email Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter. Iradimed (NASDAQ:IRMD) Frequently Asked Questions How has Iradimed's stock been impacted by COVID-19 (Coronavirus)? Iradimed's stock was trading at $22.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IRMD stock has increased by 6.3% and is now trading at $23.93. View which stocks have been most impacted by Coronavirus. When is Iradimed's next earnings date? Iradimed is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Iradimed. How were Iradimed's earnings last quarter? Iradimed Corp (NASDAQ:IRMD) issued its quarterly earnings results on Thursday, April, 30th. The medical equipment provider reported $0.18 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.15 by $0.03. The medical equipment provider had revenue of $8.68 million for the quarter, compared to analysts' expectations of $8.72 million. Iradimed had a return on equity of 17.99% and a net margin of 24.65%. View Iradimed's earnings history. What price target have analysts set for IRMD? 0 brokerages have issued 1-year price targets for Iradimed's shares. Their forecasts range from $30.00 to $30.00. On average, they expect Iradimed's stock price to reach $30.00 in the next year. This suggests a possible upside of 25.4% from the stock's current price. View analysts' price targets for Iradimed. Has Iradimed been receiving favorable news coverage? News coverage about IRMD stock has been trending negative this week, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Iradimed earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Iradimed. Who are some of Iradimed's key competitors? Some companies that are related to Iradimed include Cerus (CERS), Cardiovascular Systems (CSII), GenMark Diagnostics (GNMK), Vapotherm (VAPO), Tactile Systems Technology (TCMD), Orthopediatrics (KIDS), OraSure Technologies (OSUR), Cryolife (CRY), Invo Bioscience (IVOB), Orthofix Medical (OFIX), MiMedx Group (MDXG), SurModics (SRDX), Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT) and Co-Diagnostics (CODX). View all competitors. What other stocks do shareholders of Iradimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Micron Technology (MU), Paypal (PYPL), Crispr Therapeutics (CRSP), IntriCon (IIN), Mastercard (MA), NovaBay Pharmaceuticals (NBY) and NovaBay Pharmaceuticals (NBY). Who are Iradimed's key executives? Iradimed's management team includes the following people: Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 66)Mr. Christopher K. Scott, CFO & Sec. (Age 49)Mr. John McCreery, Chief Operating Officer (Age 64)Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 60)Mr. Louis Waldman, Controller (Age 64) What is Iradimed's stock symbol? Iradimed trades on the NASDAQ under the ticker symbol "IRMD." How do I buy shares of Iradimed? Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Iradimed's stock price today? One share of IRMD stock can currently be purchased for approximately $23.93. How big of a company is Iradimed? Iradimed has a market capitalization of $288.36 million and generates $38.52 million in revenue each year. The medical equipment provider earns $9.63 million in net income (profit) each year or $0.78 on an earnings per share basis. Iradimed employs 95 workers across the globe. What is Iradimed's official website? The official website for Iradimed is www.iradimed.com. How can I contact Iradimed? Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected] This page was last updated on 7/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
